Resources
BNET Resources
- sort by:
- Relevance
- Date
- Popularity
- EMD Serono Snags US license for Tesamorelin From Theratechnologies
- Eben Tessari submits: Theratechnologies and EMD Serono, US arm of Merck KGaA (MKGAY.PK), announced they have entered into a collaboration and licensing agreement for the exclusive commercialization rights to tesamorelin in the United States for the treatment of excess abdominal fat in HIV patients with lipodystrophy. Theratechnologies retains all...
- External links 2008-10-31
- Good Governance and Good Health: The Role of Societal Structures in the Human Immunodeficiency Virus Pandemic
- It has been argued that famine only occurs in nations that are immune to the political will of their people. Political freedom in famine free countries is additionally coupled, albeit unevenly, to other freedoms such as education, health, the control of family size and the ability to seek employment. This...
- White papers 2005-04-25
- An HIV Vaccine: As We Build It, Will They Come?
- Early researchers accurately predicted that AIDS would have a globally destructive impact. However, other experts erroneously believed that they would be able to develop a vaccine against the virus in a relatively short period. More than twenty years later, scientists continue to work to achieve this goal. This paper addresses...
- White papers 2005-06-01
- Cost-Effective Allocation of Government Funds to Prevent HIV Infection
- Relative to the magnitude of the epidemic, government funds available for HIV prevention are scarce. To optimize use of funds, the paper applies a mathematical model of the cost of HIV prevention interventions using national data on HIV risk-group size and HIV prevalence. This procedure suggested an allocation of funds...
- White papers 2005-08-01
- HHS: Efforts to Research and Inform the Public About Nonoxynol-9 and HIV
- Preventing the transmission of HIV, the virus that causes AIDS, is an important public health challenge. In the mid-1980s, researchers found that Nonoxynol-9 (N-9), a spermicide found in various contraceptive products, showed potential as a microbicide. The report reviews the efforts by federal agencies and manufacturers of contraceptive products to...
- White papers 2005-03-01
- Technology, Monopoly, and the Decline of the Viatical Settlements Industry
- The viatical settlement industry provides an opportunity for terminally-ill consumers, typically HIV patients, to exploit a previously untapped source of equity in existing life insurance contracts to finance consumption and medical expenses. The paper distinguishes two explanations for falling prices-an increase in market power, and a change in market expectations...
- White papers 2005-03-01
- The Link Between Public and Private Insurance and HIV-Related Mortality
- As policymakers consider expanding insurance coverage for HIV+ individuals, it is useful to ask if insurance has any affect on health outcomes; and, if so, whether public insurance is as efficacious as private insurance in preventing premature deaths among HIV+ patients. Using data from a nationally representative cohort of HIV-infected...
- White papers 2002-11-01
- Substance Use and High-Risk Sex Among People With HIV: A Comparison Across Exposure Groups
- Substance use is associated with increased risk for HIV transmission by HIV-positive people to uninfected partners through sexual contact. The largest risk groups for infection, men who have sex with men MSM and injecting drug users IDUs have high rates of substance use, but little is known about their substance...
- White papers 2003-06-01
- Sex Without Disclosure of Positive HIV Serostatus in a US Probability Sample of Persons Receiving Medical Care for HIV Infection
- This paper estimates the proportion of HIV-positive adults who have any sexual contact without disclosure and the proportion of their sexual partnerships that involve unprotected sex without disclosure. Overall, 42% of the gay or bisexual men, 19% of the heterosexual men, and 17% of all the women reported any sex...
- White papers 2004-09-23
- Reducing Sexual Risk Among Injection Drug Users
- Multiple sexual partnerships, sex work, and unprotected intercourse are common among injection drug users IDUs. IDUs are also more likely to engage in heterosexual anal intercourse, which is associated with greater risk for HIV transmission than is vaginal sex. Thus, reducing IDUs' sexual risk is an important step in stemming...
- White papers 2005-01-14
- HIV Testing Among Indigent Women: Who Gets Tested?
- AIDS is currently among the ten leading causes of death for women of reproductive age and the leading cause of death for African American women between the ages of 25 and 34, according to the Centers for Disease Control, which advocates recommending and routinely providing testing and counseling in settings...
- White papers 2005-02-14
- Audio Computer-Assisted Self-Interviewing (ACASI) May Avert Socially Desirable Responses About Infant Feeding in the Context of HIV
- Understanding infant feeding practices in the context of HIV and factors that put mothers at risk of HIV infection is an important step towards prevention of mother to child transmission of HIV PMTCT. Face-to-face FTF interviewing may not be a suitable way of ascertaining this information because respondents may report...
- White papers 2005-08-02
- Attracting a Positive Market
- HIV treatment medications must confront a difficult subject and still offer hope. The ads for HIV treatment medications can be found throughout the urban landscape, decorating a phone booth here, a billboard there, adding to a general acceptance of medical information in the public sphere. So how do companies position...
- White papers 2005-10-17
- Abbott Q3: How a Monopoly Over an HIV Drug Resulted in Lower Sales
- A court decision recently put a stamp of approval on Abbott's monopoly over Norvir, a protease inhibitor that functions as a booster for its HIV drug, Kaletra. But that now-legal monopoly has not resulted in increased sales, according to Abbott's Q3 2009 earnings report. by Jim Edwards
- Blog posts 2009-10-14
- Hemophiliacs Appeal Ruling That Prevents Them Suing Bayer Over HIV-Tainted Blood
- Taiwanese haemophiliacs who allege they received HIV-tainted blood products from a unit of Bayer are appealing a decision by a U.S. court that they cannot sue in America. Their claims are "dramatic," according to the Guardian. Bayer bought a company called Cutter, which made blood products for haemophiliacs: by Jim...
- Blog posts 2009-10-13
- Allergan's "Botox Parties" Could Spread HIV as Single-Use Vials Are Re-Used, Suit Claims
- Allergan pushes "Botox parties" that put people at risk of HIV and Hepatitis because a "single-use" vial of the drug is used multiple times on different guests, according to a federal lawsuit filed in California. Doctors can only make a profit using Botox if they re-use the "single-use" vials that...
- Blog posts 2009-10-05
- Merck CEO Clark Subject of "Wanted" Poster Over Price of HIV Drugs
- The AIDS Healthcare Foundation, which claims to be the U.S.'s largest provider of HIV medicine, has published a "Wanted" poster featuring Merck CEO Richard Clark to protest the "criminal" high price of Isentress. by Jim Edwards
- Blog posts 2009-09-08
- Bayer Says It Settled Decades-Old HIV-Tainted Blood Cases
- Bayer says it has entered into a settlement with "the vast majority" of plaintiffs in a decades-old piece of litigation brought by hemophiliacs who were infected with HIV-tainted blood transfusions in the 1980s. by Jim Edwards
- Blog posts 2009-08-03
- With New CV Drugs, Gilead Tests Its Commitment to Efficiency
- Gilead received some good news today with the results of a positive phase 3 study of its new high-blood pressure drug, darusentan. Combined with Gilead's purchase of CV Therapeutics to gain the chronic angina drug Ranexa, this marks a new push into the cardio-vascular area for a...
- Blog posts 2009-04-03
- It’s Good News, Bad News for Gilead’s HIV Pill
- The good news: The FDA approved Viread, Gilead’s dwindling HIV treatment, as a therapy for hepatitis B. The drug’s sales had gone down to $613 million from a peak of $783 million as newer combination drugs -- including Gilead’s own Atripla, which includes Viread -- eroded the market for standalone...
- Blog posts 2008-08-12
- << Previous
- page 1 of 3
- Next >>
Content Types
Refining Tags
- Healthcare (8 results)
- Jim Edwards (7 results)
- U.S. Department Of Health And Human Services (7 results)
- Human Resources (7 results)
- Women (6 results)
- Gender And Diversity (5 results)
- Health Care (5 results)
- Government (4 results)
- Infection (4 results)
- Patient (4 results)
- Finance (3 results)
- Business Operations (3 results)
- Gilead Sciences Inc. (3 results)
- Federal Government (3 results)
Premier Vendor Content Whitepapers, webcasts & resources from our Power Center Sponsors
